Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeu… Read more
Panacea Biotec Limited (PANACEABIO) - Total Liabilities
Latest total liabilities as of September 2025: ₹4.32 Billion INR
Based on the latest financial reports, Panacea Biotec Limited (PANACEABIO) has total liabilities worth ₹4.32 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Panacea Biotec Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Panacea Biotec Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Panacea Biotec Limited Competitors by Total Liabilities
The table below lists competitors of Panacea Biotec Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orthex Oyj
HE:ORTHEX
|
Finland | €47.28 Million |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
Brazil | R$1.93 Billion |
|
3D Global Biotech Inc.
TWO:6808
|
Taiwan | NT$152.66 Million |
|
Udaipur Cement Works Limited
NSE:UDAICEMENT
|
India | ₹18.94 Billion |
|
Panda Financial Holding Corp Ltd
SHG:600599
|
China | CN¥184.45 Million |
|
OCK Group Bhd
KLSE:0172
|
Malaysia | RM1.29 Billion |
|
Galaxy Gaming Inc
OTCQB:GLXZ
|
USA | $45.47 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Panacea Biotec Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.05 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Panacea Biotec Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Panacea Biotec Limited (2005–2025)
The table below shows the annual total liabilities of Panacea Biotec Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹4.59 Billion | +14.08% |
| 2024-03-31 | ₹4.02 Billion | -6.64% |
| 2023-03-31 | ₹4.31 Billion | -51.31% |
| 2022-03-31 | ₹8.85 Billion | -37.18% |
| 2021-03-31 | ₹14.09 Billion | +17.97% |
| 2020-03-31 | ₹11.95 Billion | +16.19% |
| 2019-03-31 | ₹10.28 Billion | -21.02% |
| 2018-03-31 | ₹13.02 Billion | -9.21% |
| 2017-03-31 | ₹14.34 Billion | +2.08% |
| 2016-03-31 | ₹14.05 Billion | -3.51% |
| 2015-03-31 | ₹14.56 Billion | +2.15% |
| 2014-03-31 | ₹14.25 Billion | +18.13% |
| 2013-03-31 | ₹12.06 Billion | +7.34% |
| 2012-03-31 | ₹11.24 Billion | +3.44% |
| 2011-03-31 | ₹10.87 Billion | +10.85% |
| 2010-03-31 | ₹9.80 Billion | -10.23% |
| 2009-03-31 | ₹10.92 Billion | +80.84% |
| 2008-03-31 | ₹6.04 Billion | +21.67% |
| 2007-03-31 | ₹4.96 Billion | -35.12% |
| 2006-03-31 | ₹7.65 Billion | +195.24% |
| 2005-03-31 | ₹2.59 Billion | -- |